Proteolytic activity of human non-Hodgkin's lymphomas

被引:0
|
作者
Kossakowska, AE
Hinek, A
Edwards, DR
Lim, MS
Zhang, CL
Breitman, DR
Prusinkiewicz, C
Stabbler, AL
Urbanski, LS
Urbanski, SJ
机构
[1] Univ Calgary, Dept Pathol, Calgary, AB T2N 1N4, Canada
[2] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 1N4, Canada
[3] Hosp Sick Children, Div Cardiovasc Res, Toronto, ON M5G 1X8, Canada
来源
AMERICAN JOURNAL OF PATHOLOGY | 1998年 / 152卷 / 02期
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study was conducted to assess the net proteolytic activity of human non-Hodgkin's lymphomas (NHLs), We have compared the extracellular matrix (ECM)-degradative abilities of human NHLs, reactive lymphoid hyperplasias, and established lymphoid cell lines using Matrigel invasion and elastin degradation assays, The inhibition studies allowed identification of the classes of proteinases involved in ECM degradation, Our results indicate that lymphocytes and other leukocytes derived from both human NHLs and reactive lymphoid hyperplasias are capable of Matrigel penetration, but only cells derived from the high-grade human NHLs degrade elastin in vitro, Established lymphoid cell lines (both malignant and Epstein-Barr virus immortalized) do not produce MMP-9, do not penetrate the Matrigel, and do not degrade elastin. Moreover, in human NHLs, elastolytic activity is blocked by metalloproteinase inhibitors, while inhibitors of the other classes of proteolytic enzymes have only minor effects. This study identifies metalloproteinases as the most important class of proteinases involved in ECM degradation by NHLs, The previous studies suggest that, within this class, MMP-9 represents the key enzyme that plays a role in the biological aggressiveness of human NHLs.
引用
收藏
页码:565 / 576
页数:12
相关论文
共 50 条
  • [31] Algorithms for Patients with non-Hodgkin's Lymphomas
    Hiddemann, W.
    Heinzelmann, F.
    ONKOLOGE, 2011, 17 (09): : 765 - +
  • [32] Non-Hodgkin's lymphomas: a short overview
    Pudasaini, S.
    Dreyling, M.
    INNERE MEDIZIN, 2025,
  • [33] Non-Hodgkin lymphomas of Waldeyer's ring
    Salplahta, D.
    Comanescu, Maria Victoria
    Anghelina, F.
    Ionita, Elena
    Mogoanta, Carmen Aurelia
    Anghelina, Liliana
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2012, 53 (04): : 1057 - 1060
  • [34] Autoimmune thrombocytopenia in non-Hodgkin's lymphomas
    Hauswirth, Alexander W.
    Skrabs, Cathrin
    Schuetzinger, Christian
    Raderer, Markus
    Chott, Andreas
    Valent, Peter
    Lechner, Klaus
    Jaeger, Ulrich
    HAEMATOLOGICA, 2008, 93 (03) : 447 - 450
  • [35] Histopathology and classification of non-Hodgkin's lymphomas
    MullerHermelink, HK
    INTERNIST, 1997, 38 (02): : 113 - 121
  • [36] Non-Hodgkin's lymphomas and organic solvents
    Rêgo, MAV
    Sousa, CSC
    Kato, M
    de Carvalho, AB
    Loomis, D
    Carvalho, FM
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2002, 44 (09) : 874 - 881
  • [37] Ofatumumab in the treatment of non-Hodgkin's lymphomas
    Karlin, Lionel
    Coiffier, Bertrand
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) : 1085 - 1091
  • [38] Sonography of cutaneous non-Hodgkin's lymphomas
    Giovagnorio, F
    CLINICAL RADIOLOGY, 1997, 52 (04) : 301 - 303
  • [39] Non-Hodgkin's lymphomas and occupation in Sweden
    María Isabel Cano
    Marina Pollán
    International Archives of Occupational and Environmental Health, 2001, 74 : 443 - 449
  • [40] Vaccine strategies in non-Hodgkin's lymphomas
    Brissinck, J
    Russell, SJ
    BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (04): : 799 - 817